Fidelity International
SMMT icon

Fidelity International’s Summit Therapeutics SMMT Stock Holding History

Fidelity International’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.03K Hold
345
– – ﹤0.01% 1138
2026
Q1 		$6.54K Buy
+345
New +$5.58K ﹤0.01% 1094
2021
Q3 		– Sell
-104,100
Closed -$777K – 888
2021
Q2 		$777K Buy
+104,100
New +$683K ﹤0.01% 759

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Fidelity International's SMMT Position: Q2 2026 in Review

Fidelity International held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 345 shares worth $5.03K. The position accounts for ﹤0.01% of the portfolio, ranked #1138.

Fidelity International first reported a position in SMMT in Q2 2021 and has held it in 3 quarters since. The position peaked at $777K in Q2 2021. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Fidelity International held 345 shares of Summit Therapeutics worth $5.03K as of Q2 2026.
  • Fidelity International left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Fidelity International's portfolio in Q2 2026, its #1138 holding.
  • Fidelity International first reported a position in Summit Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • Fidelity International's Summit Therapeutics position peaked at $777K in Q2 2021.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.